STAT September 22, 2021
The revolutionary life-extending approach to treating cancer known as CAR-T is under threat from a quotidian source: policy proposals to limit Medicare reimbursement in the outpatient setting to the average sales price of the treatment plus a small addition for overhead.
Chimeric antigen receptor T-cell (CAR-T) therapies have been changing the cancer treatment landscape. These one-time customized treatments created from an individual’s own T cells represent a significant advancement in treatment. Expanding their use across care settings is essential to improving patient outcomes and quality of life.
The economic viability of CAR-T, however, could be constrained by proposals to limit Medicare reimbursement when it is administered in outpatient settings, such as hospital outpatient and specialty cancer centers, to the average...
Today's Sponsors
Today's Sponsor